578 views · 1 likes · 0 reposts (at collection)
China floats restrictions on foreign buyouts of biotech platforms, quoted post reports
What happened
Kevin Weil links to @m_goes_distance’s post reporting that Beijing has floated restrictions on foreign buyouts of China’s cell and gene therapy and siRNA platforms, while allowing individual drug licensing. The quoted author says the draft also covers AI technology and frames platform ownership as a national security issue. The proposal remains a draft, with comments open until nov 15.
Why it matters
The distinction between licensing individual medicines and acquiring their underlying platforms provides a concrete lens for understanding the strategic ownership concerns raised by the proposed restrictions.
The story so far
Beijing has floated draft restrictions on foreign buyouts of China’s cell and gene therapy and siRNA platforms while allowing individual drug licensing, according to a post by @m_goes_distance that Kevin Weil linked to on X. The proposal remains a draft, with comments open until November 15. The quoted author said the draft also covers AI technology and treats platform ownership as a national security issue. The reported distinction is between foreign acquisition of the platforms and licensing individual drugs.
Keep reading
Latest daily · Issue 25DeepSeek releases DeepSeek-V4.1-Flash-1017 on its website, app, and APITrending now
- 1DeepSeek Releases V4.1-Flash-1017, Now Available on Ollama Cloud With US Hosting
- 2Anthropic Pledges 5% of Its Shares to New Public Benefit Fund
- 3Meta Removes Business Terms Language That Raised Website Scraping and AI Training Concerns
- 4Anthropic Says Claude Reconstructed Five NIST Elliptic-Curve Seeds Using a Timestamp-Initialized Generator
Tomorrow at 08:00, a briefing like this arrives in your inbox.
The same kind of briefing as the one above: a few stories worth reading. Free. Mail starts after you confirm, and every letter has a one-click unsubscribe. Read a past issue · 2026-10-18